Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 376 participants.
Also called NCT03386344
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 376 participants
- Sponsor
- Registry
-
NCT03386344
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Mexico, New Zealand, Russia, South Korea, Taiwan
- Registry status
- Terminated
Technical summary
Registry record NCT03386344. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-19 (actual); primary completion 2019-05-22 (actual). Results posted on 2021-06-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
- Acronym
- SOTA-BONE
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sotagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03386344- Content hash
1f02d73b09c3164f49eda1746e0efbd60ae3ab4fd65442247b2e26e56a642aaf